Trial Profile
An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of Natalizumab Following Re-Initiation of Dosing in Multiple Sclerosis Subjects Who Have Completed Study C-1801, C-1802, C-1803, or C-1808 and a Dosing Suspension Safety Evaluation
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms STRATA
- Sponsors Biogen
- 02 Apr 2022 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 01 Nov 2017 Results of pooled retrospective analysis assessing natalizumab-associated progressive multifocal leukoencephalopathy from four studies (STRATIFY-2, STRATA, TOP, and TYGRIS) published in the Lancet Neurology.
- 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.